Filogenia do gênero Spondias com base em marcadores RAPD resultados preliminares.

O trabalho teve como objetivo, estudar as relações de ancestralidade (filogenia) entre as diferentes Spondias visando agrupar as espécies/híbridos com base em marcadores de DNA do tipo RAPD

A HPLC‐DAD method for identifying and estimating the content of fucoxanthin, β‐carotene and chlorophyll a in brown algal extracts

Seaweeds are photosynthetic organisms that have high contents of pigments. The coloration of each alga is defined by the content and combination of pigments synthesized, which varies among species and environmental conditions. The most abundant pigments in algae are chlorophylls and carotenoids, lipophilic molecules that can be used as natural colorants and have high acceptance by consumers. In this work, a simple and short hands-on time HPLC-DAD method for identifying and estimating the pigment content of algal extracts, specifically fucoxanthin, β-carotene and chlorophyll a was carried out. Using this optimized method, a pigment screening was performed on the ethanolic extracts obtained by ultrasound-assisted extraction from nine brown algal from the Atlantic coastline: Ascophyllum nodosum, Bifurcaria bifurcata, Fucus spiralis, Himanthalia elongata, Laminaria saccharina, Laminaria ochroleuca, Pelvetia canaliculata, Sargassum muticum and Undaria pinnatifida. HPLC results permitted to highlight L. saccharina and U. pinnatifida as promising sources of these three target pigments containing a total amount of 10.5 – 11.5 mg per gram of dry weight. Among them, the most abundant one was fucoxanthin, an added-value compound with a high potential to be commercially exploited by different industries, such as the food, cosmetic, and pharmaceutical sectors.The research leading to these results was supported by MICINN sup- porting the Ramón y Cajal grant for M.A. Prieto (RYC-2017-22891), the FPU grant for A. Carreira-Casais (FPU2016/06135); and by Xunta de Galicia for supporting the post-doctoral grant of M. Fraga-Corral (ED481B-2019/096). The research leading to these results was sup- ported by the European Union through the “NextGenerationEU ”pro- gram supporting the “Margarita Salas ”grant awarded to P. Garcia- Perez. Authors are grateful to AlgaMar company ( www.algamar.com ) for the collaboration and algal material provision. This research was funded by the Ibero-American Program on Science and Technology (CYTED —AQUA-CIBUS, P317RT0003), the Bio Based Industries Joint Undertaking (JU) under grant agreement No 888003 UP4HEALTH Project (H2020-BBI-JTI-2019) that supports the work of C. Lourenço- Lopes. The JU receives support from the European Union’s Horizon 2020 research and innovation program and the Bio Based Industries Consor- tium. The project SYSTEMIC Knowledge hub on Nutrition and Food Se- curity, has received funding from national research funding parties in Belgium (FWO), France (INRA), Germany (BLE), Italy (MIPAAF), Latvia (IZM), Norway (RCN), Portugal (FCT), and Spain (AEI) in a joint ac- tion of JPI HDHL, JPI-OCEANS and FACCE-JPI launched in 2019 un- der the ERA-NET ERA-HDHL (n°696295). The authors would like to thank the EU and FCT for funding through the project PTDC/OCE- ETA/30240/2017- SilverBrain - From sea to brain: Green neuropro- tective extracts for nanoencapsulation and functional food production (POCI-01-0145-FEDER-030240).info:eu-repo/semantics/publishedVersio

Optimization of the Extraction Process to Obtain a Colorant Ingredient from Leaves of Ocimum basilicum var. Purpurascens

Heat-Assisted Extraction (HAE) was used for the optimized production of an extract rich in anthocyanin compounds from Ocimum basilicum var. purpurascens leaves. The optimization was performed using the response surface methodology employing a central composite experimental design with five-levels for each of the assessed variables. The independent variables studied were the extraction time (t, 20–120 min), temperature (T, 25–85 C), and solvent (S, 0–100% of ethanol, v/v). Anthocyanin compounds were analysed by HPLC-DAD-ESI/MS and the extraction yields were used as response variables. Theoretical models were developed for the obtained experimental data, then the models were validated by a selected number of statistical tests, and finally, those models were used in the prediction and optimization steps. The optimal HAE conditions for the extraction of anthocyanin compounds were: t = 65.37 3.62 min, T = 85.00 1.17 C and S = 62.50 4.24%, and originated 114.74 0.58 TA mg/g of extract. This study highlighted the red rubin basil leaves as a promising natural matrix to extract pigmented compounds, using green solvents and reduced extraction times. The extract rich in anthocyanins also showed antimicrobial and anti-proliferative properties against four human tumor cell lines, without any toxicity on a primary porcine liver cell line.The authors are grateful to the Foundation for Science and Technology (FCT, Portugal) and FEDER under Program PT2020 for financial support to CIMO (UID/AGR/00690/2013), Lillian Barros and Ricardo C. Calhelha contracts. The authors are also grateful to the Interreg España-Portugal for financial support through the project 0377_Iberphenol_6_E). This work is funded by the European Regional Development Fund (ERDF) through the Regional Operational Program North 2020, within the scope of Project Mobilizador Norte-01-0247-FEDER-024479: ValorNatural®. Authors are also grateful to Ministry of Education, Science and Technological Development, Republic of Serbia, grant No. 173032. The authors thank the GAIN (Xunta de Galicia) for financial support (P.P. 0000 421S 140.08) to Miguel A. Prieto by a post-doctoral (modality B) grant.info:eu-repo/semantics/publishedVersio

Untargeted metabolomics and in vitro functional analysis unravel the intraspecific bioactive potential of flowers from underexplored Camellia japonica cultivars facing their industrial application

The Camellia genus comprises a vast array of underexplored medicinal plants that merit a systematic valorization to exploit their potential as natural sources of phytochemicals with associated health-promoting properties. In this work, flower extracts from eight poorly characterized Camellia japonica L. cultivars were subjected to polyphenol profiling through untargeted metabolomics combined with in vitro functional analysis. Anthocyanins, mostly represented by cyanidin 3-O-glycosides, flavones, and flavonols, were found as the major constituents of C. japonica flowers, together with hydroxycinnamic acids, tyrosols, alkylphenols, and stilbenes, which were detected for the first time in this species. The application of multivariate statistics revealed a flower colordependent fingerprint of C. japonica cultivars, featuring anthocyanins and other flavonoids as metabolite markers associated with color-flowered cultivars with respect to white-flowered ones. The accumulation of anthocyanins, especially reported in ‘Eugenia de Montijo’ flowers, was highly correlated with the cytotoxic and anti-inflammatory properties of the derived extracts, including AGS, Caco-2, and MCF7 cancer cell lines. Moreover, the flavones accumulation reported in ‘Carolyn Tuttle’ extracts was also associated with high rates of free-radical scavenging activity, as well as a potent cytotoxicity against the Caco-2 cell line. In general, C. japonica anthocyanin-enriched flower extracts were revealed as promising candidates for the industrial production of polyphenols with associated biological activities of high interest for critical sectors in the food, pharmaceutical, and cosmetic industries.The research leading to these results was supported by MICINN supporting the Ramón y Cajal grant for M.A.-P. (RYC-2017–22891) and the Juan de la Cierva Formación grant for T.-O. (FJC2019–042549-I). The authors acknowledge Xunta de Galicia for funding the post-doctoral grant of L. C. (ED481B-2021/152) and the program EXCELENCIAED431F 2020/12, which supported the work by F.C. The authors are also grateful to the Foundation for Science and Technology (FCT, Portugal) for financial support through national funds FCT/MCTES (PIDDAC) to CIMO (UIDB/00690/2020 and UIDP/00690/2020) and SusTEC (LA/P/0007/2020), and national funding by FCT, P.I., through the institutional scientific employment program contract for L.-B. and R. C.-C. The work by P.G.-P. was financed by the Spanish Ministry of Universities under the application 33.50.460A.752 and by the European Union NextGenerationEU/PRTR through a Margarita Salas contract by the Universidade de Vigo.info:eu-repo/semantics/publishedVersio

Genomic DNA transposition induced by human PGBD5

Transposons are mobile genetic elements that are found in nearly all organisms, including humans. Mobilization of DNA transposons by transposase enzymes can cause genomic rearrangements, but our knowledge of human genes derived from transposases is limited. In this study, we find that the protein encoded by human PGBD5, the most evolutionarily conserved transposable element-derived gene in vertebrates, can induce stereotypical cut-and-paste DNA transposition in human cells. Genomic integration activity of PGBD5 requires distinct aspartic acid residues in its transposase domain, and specific DNA sequences containing inverted terminal repeats with similarity to piggyBac transposons. DNA transposition catalyzed by PGBD5 in human cells occurs genome-wide, with precise transposon excision and preference for insertion at TTAA sites. The apparent conservation of DNA transposition activity by PGBD5 suggests that genomic remodeling contributes to its biological function

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.MethodsWe did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805.FindingsBetween June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment.InterpretationAddition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.FundingNational Cancer Institute of the National Institutes of Health

Rubus ulmifolius Schott as a novel source of food colorant: extraction optimization of coloring pigments and incorporation in a bakery product

Color has been considered to be the flashiest attribute of foodstu s and researchers have shown a great interest in the extraction of pigmented compounds from vegetal products, with the purpose to provide alternative counterparts to the food industry; (2) Methods: This study aimed to explore Rubus ulmifolius Schott fruits as a potential source of anthocyanins, optimizing the extraction method, evaluating the bioactivity and incorporating the rich extract into a bakery food product; (3) Results: After the extraction optimization, results showed R. ulmifolius fruits to be a great source of anthocyanins, obtaining an amount of 33.58 mg AT/g E, with an extraction yield of 62.08%. The rich anthocyanin extract showed antitumor and antimicrobial potential in some tumor cell lines and strains, respectively, as well as the absence of toxicity; (4) Conclusions: The extract when incorporated in a bakery product showed a good coloring capacity, maintaining the nutritional value, revealing its use to be a great approach for replacing artificial colorants.This research was funded by the Foundation for Science and Technology (FCT, Portugal) and FEDER under Program PT2020 for financial support to CIMO (UID/AGR/00690/2019).L. Barros and R. Calhelha also thank the national funding by FCT, P.I.; through the institutional scientific employment program-contract for their contracts; Interreg España-Portugal for financial support through the project 0377_Iberphenol_6_E); and the European Regional Development Fund (ERDF) through the Regional Operational Program North 2020, within the scope of Project NORTE-01-0145-FEDER-023289: DeCodE and project Mobilizador Norte-01-0247-FEDER-024479: ValorNatural®.info:eu-repo/semantics/publishedVersio

Associations between tooth wear and dental sleep disorders : A narrative overview

Objectives Tooth wear is a common finding in adult patients with dental sleep disorders. The aim of this paper was to review the literature on the possible associations between tooth wear and the following dental sleep disorders: sleep-related oro-facial pain, oral moistening disorders, gastroesophageal reflux disease (GERD), obstructive sleep apnoea syndrome (OSAS) and sleep bruxism. Methods A PubMed search was performed on 1 June 2018 using MeSH terms in the following query: Tooth Wear AND (Facial Pain OR Temporomandibular Joint Disorders OR Xerostomia OR Sialorrhea OR Gastroesophageal Reflux OR Sleep Apnea Syndrome OR Sleep Bruxism). Results The query yielded 706 reports on tooth wear and the mentioned dental sleep disorders. Several associations between tooth wear and the dental sleep disorders were suggested in the literature. It could be concluded that: (a) tooth wear is associated with dental pain and/or hypersensitivity; (b) oral dryness is associated with tooth wear, oro-facial pain and sleep bruxism; (c) GERD is associated with tooth wear, oro-facial pain, oral dryness, OSAS and sleep bruxism; (d) OSAS is associated with oral dryness, GERD and sleep bruxism; and (e) sleep bruxism is associated with tooth wear. Conclusions Tooth wear is associated with the dental sleep disorders oro-facial pain, oral dryness, GERD and sleep bruxism. The dental sleep disorders are interlinked with each other, which leads to indirect associations as well, and makes the consequences of each single condition difficult to disentangle. Knowledge of these associations is clinically relevant, but more research is needed to confirm their validity.Peer reviewe

SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

ObjectiveLung-MAP (SWOG S1400) is a master platform trial assessing targeted therapies in squamous NSCLC. The objective of study C (S1400C) was to evaluate the response rate to palbociclib, a cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitor, in patients with cell cycle gene abnormalities.MethodsPatients with squamous NSCLC, a performance status of 0 to 2, and normal organ function who had progressed after at least one prior platinum-based chemotherapy with cyclin-dependent kinase 4 gene (CDK4) or cyclin D1 gene (CCND1), cyclin D2 gene (CCND2), or cyclin D3 gene (CCND3) amplifications on tumor specimens were eligible. The study was originally designed as a phase II/III trial comparing palbociclib with docetaxel, but it was modified to a single-arm phase II trial with the primary end point of response when immunotherapy was approved. If two or fewer responses were seen in the first 20 patients, then the study would cease enrollment.ResultsA total of 88 patients (9% of patients screened) were assigned to S1400C, and 53 patients enrolled (including 17 to receive docetaxel). One patient who had been registered to receive docetaxel was re-registered to receive palbociclib after progression while taking docetaxel. The frequencies of cell cycle gene alterations in the eligible patients taking palbociclib (n = 32) were as follows: CCND1, 81% (n = 26); CCND2, 9% (n = 3); CCND3, 6% (n = 2); and CDK4, 3% (n = 1). In all, 32 eligible patients received palbociclib. There were two partial responses (response rate 6% [95% confidence interval (CI): 0%-15%]), both with CCND1 amplification. Twelve patients had stable disease (38% [95% CI: 21%-54%]). The median progression-free survival was 1.7 months (95% CI: 1.6-2.9 months) and the median overall survival was 7.1 months (95% CI: 4.2-12.5).ConclusionPalbociclib as monotherapy failed to demonstrate the prespecified criteria for advancement to phase III testing